BerGenBio

Report Publication Announcement • May 9, 2023

BerGenBio to hold business update conference call

BerGenBio to hold business update conference call

- Management to provide clinical and financial updates, and outline proposed

rights issue -

- Webcast will take place on Monday, May 15, 2023, at 10 a.m. CEST -

BERGEN, Norway, May 9, 2023 - BerGenBio ASA (OSE: BGBIO), a clinical-stage

biopharmaceutical company developing novel, selective AXL kinase inhibitors for

severe unmet medical needs, today announced that it will hold a business update

conference call on Monday, May 15, 2023, at 10 a.m. CEST. BerGenBio's senior

management team will provide a briefing via a webcast presentation on the

Company's website, followed by a Q&A session.

Topics to be addressed during the presentation include:

Proposed Rights Issue: The Company announced on April 25, 2023, its intentions

to carry out a partially underwritten rights issue to raise gross proceeds of up

to NOK 250 million.

A Q&A document pertaining to the rights issue can from today be found in the

General Meetings (https://www.bergenbio.com/investors/general-meetings/) portion

of the Investors section of www.bergenbio.com.

BGBC008 Additional Data: Additional results of pre-planned analyses from the

Phase 2 BGBC008 trial evaluating bemcentinib in combination with pembrolizumab

in 2L+ NSCLC patients will be presented.

BGBC003 Topline Data: Topline data will be presented from the Phase 2 BGBC003

trial evaluating bemcentinib in combination with chemotherapy in patients with

AML and as a single agent in patients with MDS.

Financial Update: An update on the Company's key financial numbers will be

provided as part of the business update.

Full first quarter 2023 financial results report will currently not be

prioritized and release will be delayed to 22 June 2023.

The webcast

link (https://channel.royalcast.com/landingpage/hegnarmedia/20230515_3/) will be

available at www.bergenbio.com in the Investors/Financial Reports section.

A recording will be available shortly after the webcast has finished.

-End-

Contacts

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Investor Relations / Media Relations

Graham Morrell

graham.morrell@bergenbio.com

Media Relations

Jan Lilleby

jl@lillebyfrisch.no

+47 90 55 16 98

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing

transformative drugs targeting AXL as a potential cornerstone of therapy for

aggressive diseases, including cancer and severe respiratory infections. The

Company is focused on its proprietary lead candidate, bemcentinib, a potentially

first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC

and severe respiratory infections.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The

company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more

information, visit?www.bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not

historical facts, but are based upon various assumptions, many of which are

based, in turn, upon further assumptions. These assumptions are inherently

subject to significant known and unknown risks, uncertainties, and other

important factors. Such risks, uncertainties, contingencies and other important

factors could cause actual events to differ materially from the expectations

expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.